Full Press Release Details
Announces Presentation at the 34th Annual J.P. Morgan Healthcare
Conference in San Francisco, January 11 - 14, 2016
NEW YORK--(BUSINESS WIRE)--December 21, 2015--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR-T cells (UCART), today announced that it will be
presenting at the 34th Annual J.P. Morgan Healthcare Conference.
The Cellectis presentation will take place on Thursday, January 14,
2016, at 10:30AM Pacific Time, followed by a Q&A session at 11:00AM
Pacific Time, at the Westin St. Francis Hotel, San Francisco, California.
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited engineered CAR-T cells (UCART). The
company's mission is to develop a new generation of cancer therapies
based on engineered T-cells. Cellectis capitalizes on its 15 years of
expertise in genome engineering - based on its flagship TALEN products
and meganucleases and pioneering electroporation PulseAgile technology -
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis' goal is to create innovative products in multiple fields and
with various target markets. Cellectis S.A. is listed on the Nasdaq
Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker:
ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it.
TALEN is a registered
trademark owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
For further information:
Strategic Communications
Caitlin Kasunich, 212-896-1241
Harnest, 646-385-9008
VP Finance and Investor Relations